Please rotate your device

GET PROPEL

Stay Informed

You are leaving the HCP website

You are being directed to a third-party website. Please note that this third-party website is not controlled by PROPELOpens.com.

Thank you for visiting our site.

Continue

YOUR ACTION PLAN FOR THE
ETHMOID SINUS

Factors to consider when selecting your PROPEL tool of choice

  • PROPEL is a cylindrical-shaped implant, 23 mm in nominal length, and indicated for the ethmoid sinuses1
  • PROPEL Mini is also a cylindrical-shaped implant, but 16 mm in nominal length, and indicated for ethmoid sinus and the frontal sinus opening2

The PROPEL Mini You Know.
NOW With a Straight Delivery System

Learn more

What is the PROPEL Mini with Straight Delivery System?

PROPEL Mini with striaght delivery system

PROPEL Mini is NOW AVAILABLE WITH
a Straight Delivery System for precise
and consistent delivery into the
ethmoid sinus

  • PROPEL Mini and Straight Delivery System all in one box
  • Optimized delivery of PROPEL Mini to the ethmoid sinus
  • Precise PROPEL Mini placement for maximum tissue apposition
  • Ergonomically designed for used by any trained ENT

The PROPEL Mini sinus implant is available with either
the Curved or Straight Delivery System, in discrete packages

  SINUS
INDICATION		 DELIVERY
ANGLE		 DELIVERY
SYSTEM
DIAMETER		 CATALOG #
straight delivery system Straight
Delivery System		 Ethmoid sinus Straight 3.5 mm 60044
curved delivery system Curved
Delivery System		 Ethmoid sinus
Frontal sinus ostia		 Curved
(S-shaped)		 4.0 mm 60011
  straight delivery system curved delivery system
Straight
Delivery System		 Curved
Delivery System
SINUS
INDICATION		 Ethmoid sinus Ethmoid sinus
Frontal sinus ostia
DELIVERY
ANGLE		 Straight Curved
(S-shaped)
DELIVERY
SYSTEM
DIAMETER		 3.5 mm 4.0 mm
CATALOG # 60044 60011

Who is it for?

For your patients undergoing primary or revision ethmoid sinus surgery, who need a smaller alternative to PROPEL, with or without nasal polyps:

  • In the operating room

  • In the office

  • Following in-office procedures, such as balloon sinus dilation, ethmoidectomy, and polypectomy
  • During the postoperative healing period after sinus surgery

Watch Dr. Raithatha discuss the rationale for using PROPEL Mini deployed with the straight delivery system, in a 71-year-old male suffering from ethmoid sinus disease

HISTORY AND PRESENTING SYMPTOMS*

  • Multi-year history of chronic nasal congestion due to nasal polyps

  • Recent treatments include 3 rounds of prednisone over the past 3 months, steroid and antihistamine nasal sprays, and saline rinses

  • CT of the sinuses showed bilateral chronic pansinusitis with most involvement of his bilateral maxillary/ethmoid sinuses

  • Underwent septoplasty and bilateral endoscopic sinus surgery

  • Next steps: PROPEL Mini placement with the Straight Delivery System

*This case is intended for general medical education purposes only and is not a substitute for independent clinical medical judgment.
Response to treatment may vary from patient to patient.

Patients appropriate for PROPEL and PROPEL Mini

  • ≥18 years of age1,2

  • With and without polyps3

  • Undergoing primary or revision ethmoid sinus surgery3

PROPEL MINI is a smaller version of PROPEL, and was approved for use in the ethmoid sinus based on the demonstrated efficacy and safety profile of PROPEL2

PROPEL is the only sinus surgery implant clinically proven and supported by Level 1-A EVIDENCE to significantly improve outcomes of ethmoid sinus surgery3

Efficacy ENDPOINT: PROPEL delivers significant reduction in the need for postoperative interventions3

35
Relative
reduction

PROPEL reduced the need for postoperative interventions vs a non-drug implant, at 30 days following ethmoid sinus surgery (32.8% vs 50.8%; N=143)*†

In a subgroup analysis, both patients with and without polyps experienced significant relative reductions in the need for postoperative interventions vs a non-drug implant

36
Relative
reduction

With polyps (n=91):
36% reduction
(32.5% vs 50.6%)

35
Relative
reduction

Without polyps (n=52):
35% reduction
(33.3% vs 51.1%)

*Postoperative interventions was a composite endpoint that included surgical intervention required to separate an adhesion and/or oral steroid intervention to resolve recurrent ethmoid sinus inflammation, edema, and/or polyp recurrence.

†Judged by an independent panel.

efficacy ENDPOINTS: PROPEL delivers added benefits to patients undergoing ethmoid sinus surgery3

The benefits of PROPEL in reducing the need for postoperative interventions vs a non-drug implant following ethmoid sinus surgery were supported by reductions in oral steroids, polyposis, adhesions/scarring, and middle turbinate lateralization3

RELATIVE REDUCTIONS AT DAY 303

MT, middle turbinate.

*Judged by independent panel.

†Judged by on-site clinical investigators.

Study Design: Data presented here represent a meta-analysis of two prospective, randomized, double-blinded multicenter studies (Pilot and ADVANCE II) that enrolled a total of 143 patients. The studies evaluated outcomes of ethmoid sinus surgery with PROPEL placement compared to a non-drug implant, both with standard postoperative care. The studies used an intra-patient control design to evaluate clinical outcomes.3

Patients undergoing ESS with PROPEL resulted in significant symptom reduction through 6 months

Surgery + PROPEL significantly reduced patient-reported symptoms through 6 months following sinus surgery, as reported by SNOT-22 and RSDI1*

RSDI, Rhinosinusitis Disability Index; SNOT-22, Sino-Nasal Outcome Test-22.

*SNOT-22 evaluates rhinologic, extra-nasal rhinologic, ear/facial, psychological dysfunction and sleep dysfunction symptoms.4 RSDI evaluates physical, functional, and emotional symptoms.5

Learn more about the benefits of PROPEL after ethmoid sinus surgery

For significant improvements to patient outcomes following sinus surgery, add PROPEL to your action plan for the ethmoid sinus

PATIENT A*

Non-Drug Implant

Day 0

Day 30

PROPEL

Day 0

Day 30

*Representative outcomes in bilateral sinuses of a single patient from a PROPEL clinical study. Individual results may vary.

ethmoid case studies

Optimal treatment following ethmoid sinus surgery with a full arsenal of options including PROPEL and PROPEL Mini can help improve patient outcomes

PROPEL has a PROVEN safety profile1

The safety profile of PROPEL was established across three prospective clinical trials including 205 patients.1 The most common adverse reactions observed in ≥2% were sinusitis, headache, epistaxis, and bronchitis.

GET PROPEL

Stay Informed

This site is intended for healthcare professionals in the United States

Instructions for Use:

PROPEL PROPEL MINI PROPEL MINI WITH SDS PROPEL CONTOUR
Stay Informed

References

  1. PROPEL [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
  2. PROPEL Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
  3. Han JK, Marple BF, Smith TL, et al. Effect of steroid-releasing sinus implants on postoperative medical and surgical interventions: an efficacy meta-analysis. Int Forum Allergy Rhinol. 2012;2(4):271-279.
  4. Deconde AS, Bodner TE, Mace JC, Smith TL. Response shift in quality of life after endoscopic sinus surgery for chronic rhinosinusitis. JAMA Otolaryngol Head Neck Surg. 2014;140(8):712-719.
  5. Benninger MS, Senior BA. The development of the Rhinosinusitis Disability Index. Arch Otolaryngol Head Neck Surg. 1997;123(11):1175-1179.

The PROPEL sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL for the ethmoid sinus, PROPEL Mini for the ethmoid sinus/frontal sinus opening, and PROPEL Contour for the frontal/maxillary sinus ostia. Contraindications include patients with confirmed hypersensitivity or intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.IntersectENT.com/technologies/. Rx only.

© 2024 Intersect ENT, Inc. All rights reserved. Intersect ENT and PROPEL are registered trademarks of Intersect ENT, Inc. in the United States and other countries. MPM-11549 Rev 7.0

The above-identified implants, delivery systems, and/or the use of the above-identified implants/delivery systems in a method may be covered by one or more U.S. and/foreign patents, found at intersectent.com/patents.